Franklin Resources
YMAB

Franklin Resources’s Y-mAbs Therapeutics YMAB Stock Holding History

Franklin Resources’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-67,367
Closed -$527K – 3082
2024
Q4 		$527K Buy
67,367
+78
+0.1% +$950 ﹤0.01% 2262
2024
Q3 		$978K Buy
67,289
+312
+0.5% +$3.96K ﹤0.01% 1995
2024
Q2 		$809K Buy
66,977
+33,996
+103% +$459K ﹤0.01% 2025
2024
Q1 		$536K Buy
32,981
+17,243
+110% +$232K ﹤0.01% 2210
2023
Q4 		$107K Buy
15,738
+59
+0.4% +$341 ﹤0.01% 2461
2023
Q3 		$85.5K Sell
15,679
-21,787
-58% -$127K ﹤0.01% 2476
2023
Q2 		$254K Buy
+37,466
New +$281K ﹤0.01% 2285

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Franklin Resources's YMAB Position: Q1 2025 in Review

Franklin Resources sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 67,367 shares — an estimated $527K sold.

Franklin Resources first reported a position in YMAB in Q2 2023 and held it in 7 quarters. The position peaked at $978K in Q3 2024. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • Franklin Resources reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Franklin Resources sold 67,367 Y-mAbs Therapeutics shares in Q1 2025, an estimated $527K.
  • Franklin Resources first reported a position in Y-mAbs Therapeutics in Q2 2023 and held it in 7 quarters.
  • Franklin Resources's Y-mAbs Therapeutics position peaked at $978K in Q3 2024.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on Franklin Resources's 13F filing for Q1 2025, filed 13 May 2025.